Since n-3 PUFAs have been shown to bind efficiently to the ligand-binding domain of PPAR-γ and activate PPAR response element-reporter assays in various cell lines [12], [21], we hypothesized that EPA and DHA administration suppress the progressive properties of prostate cancer via activation of PPAR-γ involved pathway. The gene discussed is PPARG; the disease is prostate cancer.